Literature DB >> 12854741

Mutational analysis of 206 families with cavernous malformations.

Maxwell S H Laurans1, Michael L DiLuna, Dana Shin, Faheem Niazi, Jennifer R Voorhees, Carol Nelson-Williams, Eric W Johnson, Adrian M Siegel, Gary K Steinberg, Michel J Berg, R Michael Scott, Gioacchino Tedeschi, T Peter Enevoldson, John Anson, Guy A Rouleau, Christopher Ogilvy, Issam A Awad, Richard P Lifton, Murat Gunel.   

Abstract

OBJECT: A gene contributing to the autosomal-dominant cerebral cavernous malformation (CCM) phenotype, KRIT1 (an acronym for Krev Interaction Trapped 1), has been identified through linkage analysis and mutation screening. The authors collected blood samples from 68 patients with familial CCM and 138 patients with apparently sporadic CCM as well as from their families, in an effort to characterize the prevalence and spectrum of disease-causing sequence variants in the KRIT1 gene.
METHODS: The authors used single-strand conformational polymorphism analysis to identify genomic variants in KRIT1, which were sequenced to determine the specific mutation. Among 43 Hispanic-American kindreds who immigrated to the southwestern US from northern Mexico, 31 share an identical founder mutation. This Q455X mutation is found in 18 (86%) of 21 persons with a positive family history and in 13 (59%) of 22 persons with apparently sporadic CCM. This mutation was not found among 13 persons with CCM who were recruited from Mexico. These findings establish the key role of a recent founder mutation in Hispanic persons with CCM who live in the US. Although nearly all Hispanic families in the US in which there are multiple CCM cases linked to the CCM1 locus, only 13 of 25 non-Hispanic CCM-carrying families have displayed evidence of linkage to the CCM1 locus. Among these 13 families, the authors identified eight independent mutations in nine kindreds. They identified four additional mutations among 22 familial CCM kindreds with no linkage information, bringing the total number of independent mutations to 12. Inherited KRIT1 mutations were not detected among 103 non-Hispanic persons in whom a family history of CCM was rigorously excluded.
CONCLUSIONS: All mutations were nonsense mutations, frame-shift mutations predicting premature termination, or splice-site mutations located throughout the KRIT1 gene, suggesting that these are genetic loss-of-function mutations. These genetic findings, in conjunction with the clinical phenotype, are consistent with a two-hit model for the occurrence of CCM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12854741     DOI: 10.3171/jns.2003.99.1.0038

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

Review 1.  Cystic cavernous angiomas.

Authors:  Shigeo Ohba; Kazuhiko Shimizu; Syunsuke Shibao; Toru Nakagawa; Hideki Murakami
Journal:  Neurosurg Rev       Date:  2010-02-20       Impact factor: 3.042

2.  Identification of two novel mutations and of a novel critical region in the KRIT1 gene.

Authors:  Vito Guarnieri; Lucia A Muscarella; Rosina Amoroso; Alessandro Quattrone; Massimo E Abate; Michelina Coco; Domenico Catapano; Vincenzo A D'Angelo; Leopoldo Zelante; Leonardo D'Agruma
Journal:  Neurogenetics       Date:  2006-10-17       Impact factor: 2.660

Review 3.  Cerebral cavernous malformation: new molecular and clinical insights.

Authors:  N Revencu; M Vikkula
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

4.  Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations.

Authors:  Nicholas W Plummer; Carol J Gallione; Sudha Srinivasan; Jon S Zawistowski; David N Louis; Douglas A Marchuk
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 5.  Childhood stroke.

Authors:  Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber
Journal:  Nat Rev Dis Primers       Date:  2022-02-24       Impact factor: 52.329

6.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

Review 7.  Multiple cerebral cavernous malformations associated with extracranial mesenchymal anomalies.

Authors:  Ardavan Ardeshiri; Ardeshir Ardeshiri; Andres Beiras-Fernandez; Ortrud K Steinlein; Peter A Winkler
Journal:  Neurosurg Rev       Date:  2007-10-24       Impact factor: 3.042

8.  Mutations within the MGC4607 gene cause cerebral cavernous malformations.

Authors:  C Denier; S Goutagny; P Labauge; V Krivosic; M Arnoult; A Cousin; A L Benabid; J Comoy; P Frerebeau; B Gilbert; J P Houtteville; M Jan; F Lapierre; H Loiseau; P Menei; P Mercier; J J Moreau; A Nivelon-Chevallier; F Parker; A M Redondo; J M Scarabin; M Tremoulet; M Zerah; J Maciazek; E Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2004-01-22       Impact factor: 11.025

Review 9.  Multiple cavernous hemangiomas of the lung and liver mimicking metastasis: A case report and literature review.

Authors:  Bo-Wen Zhuang; Wei Li; Zhi-Feng Chen; Chuang-Jie Cao; Xiao-Yan Xie; Xiao-Hua Xie
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

Review 10.  Cerebral Cavernous Malformation: From Mechanism to Therapy.

Authors:  Daniel A Snellings; Courtney C Hong; Aileen A Ren; Miguel A Lopez-Ramirez; Romuald Girard; Abhinav Srinath; Douglas A Marchuk; Mark H Ginsberg; Issam A Awad; Mark L Kahn
Journal:  Circ Res       Date:  2021-06-24       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.